{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:19:01Z","timestamp":1773292741188,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1124\/mol.108.046847","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T00:45:30Z","timestamp":1208565930000},"page":"225-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Protection against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich\u2019s Ataxia Fibroblasts Using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class"],"prefix":"10.1016","volume":"74","author":[{"given":"C.K.","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.S.","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/mol.108.046847_REF1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-5793(00)01638-0","article-title":"Estimation of H2O2 gradients across biomembranes","volume":"475","author":"Antunes","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1124\/mol.108.046847_REF2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.1840150323","article-title":"Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture","volume":"15","author":"Baker","year":"1992","journal-title":"Hepatology"},{"key":"10.1124\/mol.108.046847_REF3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0022-2143(99)90173-7","article-title":"Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs","volume":"134","author":"Becker","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1124\/mol.108.046847_REF4","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1039\/b704102k","article-title":"Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity","volume":"30","author":"Bernhardt","year":"2007","journal-title":"Dalton Trans"},{"key":"10.1124\/mol.108.046847_REF5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"10.1124\/mol.108.046847_REF6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00775-002-0434-3","article-title":"Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease","volume":"8","author":"Chaston","year":"2003","journal-title":"J Biol Inorg Chem"},{"key":"10.1124\/mol.108.046847_REF7","doi-asserted-by":"crossref","first-page":"7365","DOI":"10.1158\/1078-0432.CCR-04-0865","article-title":"Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves Fenton-derived free radical generation","volume":"10","author":"Chaston","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.108.046847_REF8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/1531-8249(199905)45:5<673::AID-ANA20>3.0.CO;2-Q","article-title":"Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia","volume":"45","author":"Delatycki","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1124\/mol.108.046847_REF9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","article-title":"Neurological effects of high-dose idebenone in patients with Friedreich\u2019s ataxia: a randomised, placebo-controlled trial","volume":"6","author":"Di Prospero","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1124\/mol.108.046847_REF10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0300-483X(95)03301-U","article-title":"The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1\u2032ol]-2-methyl-3-hydroxypyridin-4-one in the rat","volume":"108","author":"Fredenburg","year":"1996","journal-title":"Toxicology"},{"key":"10.1124\/mol.108.046847_REF11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1155\/S1565363303000128","article-title":"Objectives and methods of iron chelation therapy","volume":"1","author":"Hershko","year":"2003","journal-title":"Bioinorg Chem Appl"},{"key":"10.1124\/mol.108.046847_REF12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1124\/mol.108.046847_REF13","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/1097-0142(20011215)92:12<3093::AID-CNCR10107>3.0.CO;2-B","article-title":"Effect of iron chelators on proliferation and iron uptake in hepatoma cells","volume":"92","author":"Kicic","year":"2001","journal-title":"Cancer"},{"key":"10.1124\/mol.108.046847_REF14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1006\/abbi.1999.1337","article-title":"Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates","volume":"368","author":"Konorev","year":"1999","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/mol.108.046847_REF15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/mol.62.4.888","article-title":"Unexpected effects of doxorubicin on iron regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity","volume":"62","author":"Kwok","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.108.046847_REF16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1067\/mlc.2001.116487","article-title":"Exploring the \u201ciron shuttle\u201d hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture","volume":"138","author":"Link","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1124\/mol.108.046847_REF17","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2002-08-2382","article-title":"Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells","volume":"101","author":"Link","year":"2003","journal-title":"Blood"},{"key":"10.1124\/mol.108.046847_REF18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/mol.108.046847_REF19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1042\/BJ20051496","article-title":"Chelation and determination of labile iron in primary by hepatocytes pyridinone fluorescent probes","volume":"395","author":"Ma","year":"2006","journal-title":"Biochem J"},{"key":"10.1124\/mol.108.046847_REF20","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2004-10-3856","article-title":"Iron trafficking in the mitochondrion: novel pathways revealed by disease","volume":"105","author":"Napier","year":"2005","journal-title":"Blood"},{"key":"10.1124\/mol.108.046847_REF21","first-page":"143","article-title":"Iron and Friedreich ataxia","volume":"70","author":"Pandolfo","year":"2006","journal-title":"J Neural Transm Suppl"},{"key":"10.1124\/mol.108.046847_REF22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0014-5793(79)80111-8","article-title":"Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent","volume":"97","author":"Ponka","year":"1979","journal-title":"FEBS Lett"},{"key":"10.1124\/mol.108.046847_REF23","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood.V72.5.1497.1497","article-title":"Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant","volume":"72","author":"Porter","year":"1988","journal-title":"Blood"},{"key":"10.1124\/mol.108.046847_REF24","first-page":"685","article-title":"The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell","volume":"54","author":"Richardson","year":"1994","journal-title":"Cancer Res"},{"key":"10.1124\/mol.108.046847_REF25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mlc.2001.114105","article-title":"The controversial role of deferiprone in the treatment of thalassemia","volume":"137","author":"Richardson","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1124\/mol.108.046847_REF26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4889(90)90018-9","article-title":"The uptake of iron and transferrin by the human malignant melanoma cell","volume":"1053","author":"Richardson","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.108.046847_REF27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0167-4889(91)90192-Z","article-title":"The release of iron and transferrin by the human malignant melanoma cell","volume":"1091","author":"Richardson","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.108.046847_REF28","doi-asserted-by":"crossref","first-page":"21384","DOI":"10.1016\/S0021-9258(19)36621-9","article-title":"Intermediate steps in cellular iron uptake from transferrin. Detection of a cytoplasmic pool of iron, free of transferrin","volume":"267","author":"Richardson","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.108.046847_REF29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/jcp.1041610119","article-title":"Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: the effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake","volume":"161","author":"Richardson","year":"1994","journal-title":"J Cell Physiol"},{"key":"10.1124\/mol.108.046847_REF30","first-page":"660","article-title":"The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis","volume":"124","author":"Richardson","year":"1994","journal-title":"J Lab Clin Med"},{"key":"10.1124\/mol.108.046847_REF30a","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2143(98)90180-9","article-title":"Pyridoxal isonicotinoyl hydrazone and its analogues: potential orally effective iron-chelating agents for the treatment of iron overload disease","volume":"131","author":"Richardson","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1124\/mol.108.046847_REF32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(01)00041-2","article-title":"Development of potential iron chelators for the treatment of Friedreich\u2019s ataxia: ligands that mobilize mitochondrial iron","volume":"1536","author":"Richardson","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.108.046847_REF33","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood.V86.11.4295.bloodjournal86114295","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents","volume":"86","author":"Richardson","year":"1995","journal-title":"Blood"},{"key":"10.1124\/mol.108.046847_REF34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/10715760290021333","article-title":"Heart hypertrophy and function are improved by idebenone in Friedreich\u2019s ataxia","volume":"36","author":"Rustin","year":"2002","journal-title":"Free Radic Res"},{"key":"10.1124\/mol.108.046847_REF35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0167-4889(92)90131-T","article-title":"A low-spin iron complex in human melanoma and rat hepatoma cells and a high-spin iron(II) complex in rat hepatoma cells","volume":"1135","author":"St Pierre","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.108.046847_REF36","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.1074\/jbc.M408717200","article-title":"Friedreich\u2019s ataxia, no changes in mitochondrial labile iron in human lymphoblasts and fibroblasts: a decrease in antioxidative capacity?","volume":"280","author":"Sturm","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.108.046847_REF37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/hmg\/8.3.425","article-title":"The Friedreich\u2019s ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis","volume":"8","author":"Wong","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1124\/mol.108.046847_REF38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/15230860050192233","article-title":"Sensitivity of FRDA lymphoblasts to salts of transition metal ions","volume":"2","author":"Wong","year":"2000","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/mol.108.046847_REF39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2004.09.001","article-title":"PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice","volume":"1739","author":"Wong","year":"2004","journal-title":"Biochim Biophys Acta"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2404923X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2404923X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.108.046847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:56:10Z","timestamp":1739966170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X2404923X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0026895X2404923X"],"URL":"https:\/\/doi.org\/10.1124\/mol.108.046847","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protection against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich\u2019s Ataxia Fibroblasts Using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.108.046847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2008 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}